{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:50:33Z","timestamp":1775137833810,"version":"3.50.1"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>\n                    The emergence of antimicrobial-resistant\n                    <jats:italic toggle=\"yes\">Neisseria gonorrhoeae<\/jats:italic>\n                    has become a critical global health challenge, compromising the effectiveness of existing treatment regimens. Gepotidacin (GSK2140944), a first-in-class, orally administered triazaacenaphthylene antibiotic, offers a promising therapeutic alternative due to its novel dual-target inhibition of DNA gyrase and topoisomerase IV. This review summarizes current evidence on gepotidacin\u2019s role in the management of uncomplicated urogenital gonorrhea. Findings from Phase II and Phase III clinical trials demonstrate microbiological cure rates exceeding 90%, comparable to the current ceftriaxone-based standard of care, with a favorable safety profile. Gepotidacin\u2019s oral route, effectiveness against resistant strains, and utility for patients unable to receive cephalosporins or fluoroquinolones position it as a significant advancement in sexually transmitted infection management. Its introduction may strengthen antimicrobial stewardship, reduce complications, and enhance accessibility, particularly in low- and middle-income countries. Collectively, gepotidacin represents a major step forward in combating resistant gonorrhea and shaping future antibiotic development.\n                  <\/jats:p>","DOI":"10.1097\/ms9.0000000000004841","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:00:35Z","timestamp":1774620035000},"page":"2719-2721","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A new chapter in STI management: gepotidacin\u2019s role in gonorrhea treatment"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6248-5023","authenticated-orcid":false,"given":"Zahabia","family":"Adnan","sequence":"first","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajra","family":"Rauf","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2930-8188","authenticated-orcid":false,"given":"Ahmed Asad","family":"Raza","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2676-9093","authenticated-orcid":false,"given":"Abedin","family":"Samadi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kabul University of Medical Sciences, Abu Ali Sina, Kabul, Afghanistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"R2-20260402","doi-asserted-by":"crossref","first-page":"1911\u201316","DOI":"10.15585\/mmwr.mm6950a6","article-title":"Update to CDC\u2019s treatment guidelines for gonococcal infection, 2020","volume":"69","author":"St Cyr","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R3-20260402","first-page":"9629761","article-title":"A rare case of disseminated pyogenic gonococcal infection in an immunocompetent woman","volume":"2016","author":"Romiopoulos","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"R4-20260402","doi-asserted-by":"crossref","first-page":"1621\u201323","DOI":"10.1093\/cid\/ciz145","article-title":"Risk of ectopic pregnancy and tubal infertility following gonorrhea and chlamydia infections","volume":"69","author":"Reekie","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R5-20260402","doi-asserted-by":"crossref","first-page":"1608\u201320","DOI":"10.1016\/S0140-6736(25)00628-2","article-title":"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study","volume":"405","author":"Ross","year":"2025","journal-title":"Lancet"},{"key":"R6-20260402","doi-asserted-by":"crossref","first-page":"504\u201312","DOI":"10.1093\/cid\/ciy145","article-title":"Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation","volume":"67","author":"Taylor","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R7-20260402","doi-asserted-by":"crossref","first-page":"3093\u2013105","DOI":"10.1021\/acsinfecdis.5c00497","article-title":"Mechanism of action of gepotidacin: well-balanced dual-targeting against Neisseria gonorrhoeae gyrase and topoisomerase iv in cells and in vitro","volume":"11","author":"Oviatt","year":"2025","journal-title":"ACS Infect Dis"},{"key":"R8-20260402","doi-asserted-by":"crossref","first-page":"3109\u201319","DOI":"10.1093\/jac\/dkaa300","article-title":"Treatment efficacy for pharyngeal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials","volume":"75","author":"Kong","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R9-20260402","doi-asserted-by":"crossref","first-page":"e00199","DOI":"10.1128\/AAC.00199-20","article-title":"Phase 2a pharmacokinetic, safety, and exploratory efficacy evaluation of oral gepotidacin (GSK2140944) in female participants with uncomplicated urinary tract infection (acute uncomplicated cystitis)","volume":"64","author":"Overcash","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-20260402","first-page":"100082","article-title":"Transparency In The reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Premier J Sci"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:00:32Z","timestamp":1775134832000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004841","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"2025-12-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}